drugset / Trial / NCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Timeline
- Start
- 2018-06-18
- Primary completion
- 2020-10-07
- Completion
- 2020-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tuparstobart | Monoclonal antibody | — | Intravenous |
Indications
cervical cancer
colorectal cancer
cutaneous neuroendocrine carcinoma
diffuse large B-cell lymphoma
endometrial cancer
esophageal cancer
gastric cancer
head and neck squamous cell carcinoma
hepatocellular carcinoma
melanoma
mesothelioma
non-small cell lung carcinoma
ovarian cancer
renal cell carcinoma
small cell lung carcinoma
triple-negative breast carcinoma
urothelial carcinoma